AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

ACTengine® IMA203 Combined With mRNA-4203

RecruitingPhase 1Ages 18 Years - anyAllImmatics US, Inc.
💬

In plain words

What the trial is, and whether it could suit you

This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Pathologically confirmed and documented cutaneous melanoma (CM) or synovial sarcoma (SS) with unresectable or metastatic disease * HLA-A\*02:01 positive * Adequate selected organ function per protocol * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) * Life expectancy more than 5 months * CM participants who must have disease progression (resistance, toxicity) on or after at least one PD-1 inhibitor * SS participants must have received (or declined) at least one line of treatment (including SoC) and are still in need of further systemic therapy. * Female participants of childbearing potential must use adequate contraception prior to trial entry until 12 months after the infusion of IMA203 and 15 days after the last mRNA 4203 dose administration Other protocol defined inclusion criteria could apply Exclusion Criteria: * History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years * Pregnant or breastfeeding * Serious autoimmune disease * History of cardiac conditions as per protocol * Prior allogenic stem cell transplantation or solid organ transplantation * Concurrent severe and/or uncontrolled medical disease that could compromise participation in the study * History of hypersensitivity to cyclophosphamide, fludarabine, or IL-2 * History of hypersensitivity to mRNA-based medicines * Positive for HIV infection or with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection * Any condition contraindicating leukapheresis * Participants with lactate dehydrogenase (LDH) greater than threshold allowed per protocol * Participants with active brain metastases prior to lymphodepletion * Concurrent treatment in another clinical trial or a device trial that could interfere with the IMA203 treatment * Participants with renal impairment AND reduced bone marrow reserve per protocol Other protocol defined exclusion criteria could apply
💊

What it tests

  • IMA203
  • mRNA-4203
📍

Where

4 sites
University of California San Francisco
San Francisco, United States
Dana Farber Cancer Institute
Boston, United States
Memorial Sloan Kettering Cancer Center
New York, United States
MD Anderson Cancer Center
Houston, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy